

30 March 2020

ASX ANNOUNCEMENT

IMEXHS (ASX: IME)

Coronavirus Pandemic Update

Key Points

- Operations not expected to be materially impacted by COVID-19 pandemic containment measures
- Significant locked-in revenue with financially-secure customers
- Staff remain healthy and well positioned to continue to service customers remotely
- Benefits of HIRUKO's cloud based, tele-radiology solutions being realised by customers
- Strong financial position and significant liquidity

Imaging software solutions provider **IMEXHS Limited ("IMEXHS" or "the Company")** provides an update on the Company's operations due to the rapidly changing business environment resulting from the Coronavirus Pandemic (COVID-19).

IMEXHS is proactively managing its business to ensure; the health and safety of its staff and the continued service of its customers, who as health care professionals are in many instances on the front line of the pandemic.

To date the Company's operations have not been impacted by the COVID-19 pandemic. In early March 2020 when the COVID-19 outbreak escalated, IMEXHS put in place procedures from home protocols to reduce the public exposure of its staff and ensure that the Company could continue to provide a high level of service to its customers.

The Company's recurring revenue base is secure with the majority of IMEXHS's SaaS contracts having 5-7-year terms and fixed prices. The remaining volume-based contracts are comprised of a mixture of in-patient and out-patient services.

Medical imaging, most commonly through chest x-rays and CT scans, is an essential step in diagnosing and monitoring COVID-19. As a result, the Company expects there will be an increase in the level of services provided for in-patient services, however the Company also expects there to be a decrease for less-urgent out-patient services. The net impact of these changes is expected to be immaterial.

A key benefit of HIRUKO's architecture is the inherent design to allow remote working. In the short-term, the Company expects the sales cycle may be slowed as potential clients divert their resources to cope with COVID-19, however, in the medium and long terms, the need for the ability to work remotely may accelerate demand for IMEXHS's cloud based, tele-medicine solutions.

IMEXHS maintains a strong financial position, with good liquidity as the Company navigates the constantly evolving operating environment.

IMEXHS Limited ACN 096 687 839 122 O'Riordan Street, Mascot NSW 2020

Tel: +61 2 9030 0040



IMEXHS CEO, Dr German Arango said "We responded pro-actively to ensure the well-being of our staff and the continued service of our customers, who are playing a key role in diagnosing and monitoring the progress of COVID-19 cases. The benefits of HIRUKO's web architecture and leading tele-radiology capabilities have never been clearer. The Company is also in a strong financial position with good liquidity in this uncertain time."

Authorised for release by the Board of directors of IMEXHS Limited.

-ENDS-

For more information, please contact: Australian Media and Investor Relations Francoise Dixon, Citadel-MAGNUS E: fdixon@citadelmagnus.com

T: +61 (0) 2-8234-0112

Business Inquiries

Tony Thomas – CFO IMEXHS E: enquiries@imexhs.com.au T: +61 (0)2-9030-0040

About IMEXHS

IMEXHS Limited [ASX: IME] is a leading imaging Software as a Service (SaaS) and ancillary solutions provider. Founded in 2012, IMEXHS is known for its innovation in the imaging services market, offering flexible and scalable imaging solutions via its HIRUKO branded suite of solutions for next generation Picture Archiving and Communications System (PACS) and integrated Radiology Information System (RIS). The HIRUKO system is completely cloud based, vendor neutral and zero footprint with no need for installed software. Enhanced features such as a fully web-based voice recognition option and a zero footprint DICOM viewer are some of its advanced features. In addition to PACS and RIS, imaging technology and management systems can be provided on a Platform as a Service (PaaS) basis when packaged with equipment. The IMEXHS products are designed to increase productivity and save money for the users, with a scalable platform that is configured for the future, while enhancing patient outcomes. Please see www.imexhs.com

IMEXHS Limited ACN 096 687 839 122 O'Riordan Street, Mascot NSW 2020

Tel: +61 2 9030 0040